Halozyme Therapeutics stock closed at USD 121.84, 0.49 percent below its 52-week high

Published on 10/17/2026 at 21:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

HALO gained 81.04 percent year to date by October 16, 2026. Halozyme Therapeutics stock cost USD 121.84, up 0.27 percent versus the Nasdaq close.

Price position and upcoming results

Halozyme Therapeutics stood 0.49 percent below its 52-week high on October 16, 2026.
HALO delivered an 81.04 percent year-to-date gain as of October 16, 2026.
Halozyme Therapeutics stock stood at USD 121.84 at 4:00 p.m. ET on October 16, 2026, up 0.27 percent on Nasdaq versus the prior close of October 15, 2026.
Halozyme is scheduled to report third-quarter 2026 results on November 2, 2026, with consensus revenue at USD 490.85 million.

HALO, US40637H1095, Illustration mit AI erstellt.

Halozyme Therapeutics stock stood 0.49 percent below its 52-week high in the latest completed session. The shares last stood at USD 121.84 at 4:00 p.m. ET on October 16, 2026, up 0.27 percent on Nasdaq versus the prior close of October 15, 2026.

Year-to-date gain reaches 81.04 percent

The broader price picture remains defined by an 81.04 percent year-to-date gain as of October 16, 2026. Yahoo Finance also lists a 52-week range of USD 61.23 to USD 122.44, placing the latest price USD 0.60 below the upper end of that range.

Quarterly revenue reaches USD 481.00 million

Halozyme reported USD 481.00 million in revenue and USD 229.91 million in net income for the second quarter of 2026, according to Yahoo Finance. The company posted a 47.70 percent year-over-year revenue increase in that quarter, while the net margin was 47.80 percent.

What follows the October 16 close?

Halozyme is scheduled to report third-quarter 2026 results on November 2, 2026, after the market closes, with a conference call at 4:30 p.m. ET. MarketBeat lists consensus revenue of USD 490.85 million and consensus earnings of USD 2.30 per share for that report.

Comparison with peers

HALO (Nasdaq, USD): plus 0.27 percent, P/E 35.63, market capitalization USD 13.8 billion.

Alnylam Pharmaceuticals (Nasdaq, USD): minus 0.94 percent, P/E 39.16, market capitalization USD 31.0 billion.

Sarepta Therapeutics (Nasdaq, USD): minus 3.88 percent, P/E minus 5.90, market capitalization USD 1.8 billion.

Price remains near the yearly high

The latest price is USD 121.84 at 4:00 p.m. ET on October 16, 2026. The distance to the 52-week high is 0.49 percent, while the year-to-date gain is 81.04 percent.